Faricimab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Faricimab
Monoclonal antibody
Type?
SourceHumanized
TargetVEGF-A, angiopoietin 2
Clinical data
ATC code
  • none
Identifiers
CAS Number

Faricimab (INN[1]) is a bispecific monoclonal antibody that is being investigated for diabetic macular edema.

This drug is being developed by Hoffmann-La Roche. As of 2018, faricimab is undergoing Phase III trials.

References[edit]

  1. ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 118" (PDF). WHO Drug Information. 31 (4).